Mechanism-based pharmacokinetic/pharmacodynamic modeling of the glucagon-like peptide-1 receptor agonist exenatide to characterize its antiobesity effects in diet-induced obese mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 362, Issue 3, 2017, Pages 441-449

  Iwasaki, Shinji ^a   Hamada, Teruki ^a   Chisaki, Ikumi ^a   Andou, Tomohiro ^b   Sano, Noriyasu ^a   Furuta, Atsutoshi ^a   Amano, Nobuyuki ^a  

^a Drug Metabolism and Pharmacokinetics Research Laboratories   (United States)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; VENOM;

AGONISTS; ANIMAL; BIOLOGICAL MODEL; BODY WEIGHT; C57BL MOUSE; DRUG EFFECTS; LIPID DIET; MALE; METABOLISM; OBESITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; DIET, HIGH-FAT; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INFUSIONS, SUBCUTANEOUS; INJECTIONS, SUBCUTANEOUS; MALE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; OBESITY; PEPTIDES; VENOMS;

EID: 85027505614     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.117.242651     Document Type: Article

References (30)

1. Apovian CM, Bergenstal RM, Cuddihy RM, Qu Y, Lenox S, Lewis MS, and Glass LC (2010) Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 123:468 e9-e17.
2. Arakawa M, Ebato C, Mita T, Hirose T, Kawamori R, Fujitani Y, and Watada H (2009) Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents. Biochem Biophys Res Commun 390:809-814.
3. Baggio LL and Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157.
4. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, and Porter LE; DURATION-2 Study Group (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial. Lancet 376: 431-439.
5. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, and Baron AD; Exenatide-113 Clinical Study Group (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-Treated patients with type 2 diabetes. Diabetes Care 27:2628-2635.
6. Bush EN, Shapiro R, Brune ME, Knourek-Segel VE, Droz BA, Fey T, Lin E, and Jacobson PB (2006) Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice. Endocrine 29:375-381.
7. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, and Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-Treated patients with type 2 diabetes. Diabetes Care 28:1092-1100.
8. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, and Porter L; DURATION-1 Study Group (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet 372:1240-1250.
9. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, and Bloom SR (2001) Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155-E161.
10. Eng J, Kleinman WA, Singh L, Singh G, and Raufman JP (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402-7405.
11. Fineman M, Flanagan S, Taylor K, Aisporna M, Shen LZ, Mace KF, Walsh B, Diamant M, Cirincione B, Kothare P, et al. (2011) Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 50:65-74.
12. Gao W and Jusko WJ (2011) Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. J Pharmacol Exp Ther 336: 881-890.
13. Gao W and Jusko WJ (2012) Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. Drug Metab Dispos 40: 990-997.
14. Gennemark P, Hjorth S, and Gabrielsson J (2015) Modeling energy intake by adding homeostatic feedback and drug intervention. J Pharmacokinet Pharmacodyn 42: 79-96.
15. Göke R, Larsen PJ, Mikkelsen JD, and Sheikh SP (1995) Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary. Neuroendocrinology 62:130-134.
16. Heilbronn LK, de Jonge L, Frisard MI, DeLany JP, Larson-Meyer DE, Rood J, Nguyen T, Martin CK, Volaufova J, Most MM, et al.; Pennington CALERIE Team (2006) Effect of 6-month calorie restriction on biomarkers of longevity, metabolic adaptation, and oxidative stress in overweight individuals: A randomized controlled trial. JAMA 295:1539-1548.
17. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, and Brodows RG; GWAA Study Group (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 143: 559-569.
18. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, and Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091.
19. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, and Taylor K (2007) Effects of once-weekly dosing of a long-Acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30: 1487-1493.
20. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, and Baron AD (2005) Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 62:173-181.
21. Li H, Xu J, and Fan X (2015) Target-mediated pharmacokinetic/pharmacodynamic model based meta-Analysis and dosing regimen optimization of a long-Acting release formulation of exenatide in patients with type 2 diabetes mellitus. JPharmacol Sci 127:170-180.
22. Madsbad S (2009) Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 23:463-477.
23. Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, and Holst JJ (2011) An overview of once-weekly glucagon-like peptide-1 receptor agonists-Available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 13:394-407.
24. Mager DE, Abernethy DR, Egan JM, and Elahi D (2004) Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. J Pharmacol Exp Ther 311:830-835.
25. Mager DE, Wyska E, and Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510-518.
26. Matsui Y, Hirasawa Y, Sugiura T, Toyoshi T, Kyuki K, and Ito M (2010) Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6J mice. Biol Pharm Bull 33:963-970.
27. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, and Trautmann M (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia 50: 259-267.
28. Nielsen LL, Young AA, and Parkes DG (2004) Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117:77-88.
29. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, and Denaro M (1999) Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034.
30. Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, and Brodows RG (2007) The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 146:477-485.